A risk score predicted prolonged radiotherapy completion in locally advanced cervical cancer
A score above seven identified patients with treatment beyond 56 days in 53.6% versus 17.8% at lower scores.
A score above seven identified patients with treatment beyond 56 days in 53.6% versus 17.8% at lower scores.
Adding radiotherapy to systemic treatment was associated with longer overall and progression-free survival without significantly higher acute toxicity.
A nodal-to-primary tumor volume ratio of at least 15% was associated with lower three-year distant metastasis-free survival after extended-field radiotherapy.
Induction chemotherapy showed no overall survival benefit, with outcomes differing by disease risk and the intensity of pre-radiotherapy treatment.
Semi-automated trajectory planning reduced workflow time and needle use while maintaining clinically acceptable target coverage and organ-at-risk doses.